📊 ENTX Key Takeaways
Is Entera Bio Ltd. (ENTX) a Good Investment?
Entera Bio is a pre-revenue biotech company with zero reported sales (-76.8% YoY) and substantial operating losses of $3.5M per quarter, generating negative operating and free cash flows of -$3.1M. With only $4.1M in cash and current burn rate, the company has approximately 1-2 quarters of runway remaining, creating an acute solvency risk absent immediate capital infusion or revenue generation.
Entera Bio's fundamentals reflect a pre-commercial biotech profile: negligible revenue, no gross profit, and very large operating and net losses relative to sales. The balance sheet is clean, with strong liquidity, substantial cash relative to liabilities, and no meaningful debt, but the business still depends on improving clinical/commercial execution before the current cash runway is exhausted.
Entera Bio Ltd. Key Strengths (ENTX)
- Zero debt and clean balance sheet (Debt/Equity: 0.00x)
- Strong short-term liquidity (Current Ratio: 7.93x, Quick Ratio: 7.93x)
- Insider trading activity (10 Form 4 filings) suggests continued stakeholder engagement
- Strong liquidity with current and quick ratios of 10.83x
- Low financial leverage with essentially no long-term debt
- Solid equity base of $15.23M versus only $2.17M in liabilities
ENTX Stock Risks: Entera Bio Ltd. Investment Risks
- Zero/near-zero revenue with 76.8% YoY decline indicates failed commercialization or product launch
- Negative operating cash flow of $3.1M per quarter with only $4.1M cash = critical runway of 1-2 quarters
- Severe shareholder dilution evidenced by positive EPS despite negative net income, eroding per-share value
- Pre-revenue biotech with no visible path to profitability or product market fit
- Revenue base is immaterial at just $42K, indicating weak current operating scale
- Severe negative profitability with operating income of -$8.49M and net margin around -20055%
- Negative operating cash flow and free cash flow suggest continued cash burn and future funding risk
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue recognition and commercial product launch timeline
- Operating cash flow inflection toward positive territory
- Quarterly operating cash burn relative to cash balance
- Revenue growth and progress toward sustainable gross profit
Entera Bio Ltd. (ENTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.93x current ratio provides a solid financial cushion.
ENTX Profit Margin, ROE & Profitability Analysis
ENTX vs Healthcare Sector: How Entera Bio Ltd. Compares
How Entera Bio Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Entera Bio Ltd. Stock Overvalued? ENTX Valuation Analysis 2026
Based on fundamental analysis, Entera Bio Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Entera Bio Ltd. Balance Sheet: ENTX Debt, Cash & Liquidity
ENTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Entera Bio Ltd.'s revenue has declined by 68% over the 5-year period, indicating business contraction. The most recent EPS of $0.25 reflects profitable operations.
ENTX Revenue Growth, EPS Growth & YoY Performance
ENTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$2.6M | $0.06 |
| Q3 2025 | N/A | -$3.0M | $0.07 |
| Q2 2025 | N/A | -$2.1M | $0.06 |
| Q1 2025 | N/A | -$2.0M | $0.05 |
| Q3 2024 | N/A | -$2.4M | $0.08 |
| Q2 2024 | N/A | -$2.1M | $0.06 |
| Q3 2023 | N/A | -$2.4M | $0.08 |
| Q2 2023 | N/A | -$2.3M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Entera Bio Ltd. Dividends, Buybacks & Capital Allocation
ENTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Entera Bio Ltd. (CIK: 0001638097)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTX
What is the AI rating for ENTX?
Entera Bio Ltd. (ENTX) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTX's key strengths?
Claude: Zero debt and clean balance sheet (Debt/Equity: 0.00x). Strong short-term liquidity (Current Ratio: 7.93x, Quick Ratio: 7.93x). ChatGPT: Strong liquidity with current and quick ratios of 10.83x. Low financial leverage with essentially no long-term debt.
What are the risks of investing in ENTX?
Claude: Zero/near-zero revenue with 76.8% YoY decline indicates failed commercialization or product launch. Negative operating cash flow of $3.1M per quarter with only $4.1M cash = critical runway of 1-2 quarters. ChatGPT: Revenue base is immaterial at just $42K, indicating weak current operating scale. Severe negative profitability with operating income of -$8.49M and net margin around -20055%.
What is ENTX's revenue and growth?
Entera Bio Ltd. reported revenue of $0.0.
Does ENTX pay dividends?
Entera Bio Ltd. does not currently pay dividends.
Where can I find ENTX SEC filings?
Official SEC filings for Entera Bio Ltd. (CIK: 0001638097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTX's EPS?
Entera Bio Ltd. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ENTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Entera Bio Ltd. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ENTX stock overvalued or undervalued?
Valuation metrics for ENTX: ROE of -32.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ENTX's AI grade for 2026?
Our dual AI analysis gives Entera Bio Ltd. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTX's free cash flow?
Entera Bio Ltd.'s operating cash flow is $-3.1M, with capital expenditures of $0.0.
How does ENTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -32.8% (avg: 15%), current ratio 7.93 (avg: 2).